Femoral vein transposition arteriovenous fistula (FV tAVF) has been used for vascular access in hemodialysis patients with exhausted upper limb options or central venous occlusion. This study evaluated the safety and 60-month primary patency of femoral vein FV tAVFs for hemodialysis access.
Methods:
This multicenter, retrospective study included 32 adult patients undergoing FV tAVF creation. Patients included in the study had exhaustion or unavailability of upper arm veins or bilateral upper central venous occlusion and adequate lower extremity circulation. Primary and secondary patency rates were evaluated at 6, 12, 24, and 60 months. Complications were also analyzed. Exploratory analyses included the impact of demographic and clinical variables on primary and secondary patency rates.
Results:
Technical success was achieved in 90.63% of cases. Primary patency rates were 90.63% at 6 months, 84.38% at 12 months, 60% at 24 months, and 18.18% at 60 months. Secondary patency rates were 90.63% at 6 and 12 months, 79.31% at 24 months, and 36.84% at 60 months. Wound complications occurred in 46.88% of patients, with most managed conservatively. Steal syndrome and venous thrombosis were observed in 18.15% and 12.5% of patients, respectively. Female sex and wound complications impacted secondary patency, while a shorter duration of hemodialysis (<27 months) correlated with higher primary patency loss.
Conclusion:
FV tAVF is a feasible and reliable vascular access option for complex patients, providing robust maturation and patency rates, with manageable complication profiles.
LeeT.Fistula first initiative: historical impact on vascular access practice patterns and influence on future vascular access care. Cardiovasc Eng Technol2017; 8: 244–254.
ArhuideseIJOrandiBJNejimB, et al. Utilization, patency, and complications associated with vascular access for hemodialysis in the United States. J Vasc Surg2018; 68: 1166–1174.
4.
AlmasriJAlsawasMMainouM, et al. Outcomes of vascular access for hemodialysis: a systematic review and meta-analysis. J Vasc Surg2016; 64: 236–243.
5.
BrayBDBoydJDalyC, et al. Vascular access type and risk of mortality in a national prospective cohort of haemodialysis patients. QJM2012; 105: 1097–1103.
6.
StockschläderLMargaryanDOmranS, et al. Characteristics and outcome of vascular graft infections: a risk factor and survival analysis. Open Forum Infect Dis2024; 11: ofae271.
7.
Roy-ChaudhuryPSukhatmeVPCheungAK.Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. J Am Soc Nephrol2006; 17: 1112–1127.
8.
AllonMRobbinML.Increasing arteriovenous fistulas in hemodialysis patients: problems and solutions. Kidney Int2002; 62: 1109–1124.
9.
MacRaeJMAhmedAJohnsonN, et al. Central vein stenosis: a common problem in patients on hemodialysis. ASAIO J2005; 51: 77–81.
10.
LokCEHuberTSLeeT, et al. KDOQI clinical practice guideline for vascular access: 2019 update. Am J Kidney Dis2020; 75: S1–S164.
11.
RehmanZUArhamASophieZ.Femoral vein transposition arteriovenous fistula is a feasible option in “selected” patients as hemodialysis access. Ann Vasc Dis2019; 12: 25–29.
12.
LefroyRDattaniNReyesM, et al. The transposed femoral vein fistula: the native choice in desperate vascular access. Ann Vasc Surg2019; 54: 318–327.
13.
HuberTSOzakiCKFlynnTC, et al. Use of superficial femoral vein for hemodialysis arteriovenous access. J Vasc Surg2000; 31: 1038–1041.
14.
RuedaCANehlerMRKimballTA, et al. Arteriovenous fistula construction using femoral vein in the thigh and upper extremity: single-center experience. Ann Vasc Surg2008; 22: 806–814.
LadenheimEDLulicDLumC, et al. Primary and secondary patencies of transposed femoral vein fistulas are significantly greater than with the HeRO graft. J Vasc Access2017; 18: 232–237.
17.
BourquelotPRawaMVan LaereO, et al. Long-term results of femoral vein transposition for autogenous arteriovenous hemodialysis access. J Vasc Surg2012; 56: 440–445.
18.
SidawyANGrayRBesarabA, et al. Recommended standards for reports dealing with arteriovenous hemodialysis accesses. J Vasc Surg2002; 35: 603–610.
19.
ScollayJMSkipworthRJESevernA, et al. Vascular access using the superficial femoral vein. J Vasc Access2010; 11: 312–315.
20.
GradmanWSCohenWHaji-AghaiiM.Arteriovenous fistula construction in the thigh with transposed superficial femoral vein: our initial experience. J Vasc Surg2001; 33: 968–975.
21.
HazinedaroğluSMTüzünerAAyliD, et al. Femoral vein transposition versus femoral loop grafts for hemodialysis: a prospective evaluation. Transplant Proc2004; 36: 65–67.
GoodkinDAPortFK.Venous access: are women equal?Am J Kidney Dis2003; 42: 428; author reply 429.
24.
GroenenHBontekoningNVan DierenS, et al. Patients’ ability to self-manage their surgical wound to prevent wound complications: a cross-sectional study. J Adv Nurs2025; 81: 4208–4215.
25.
MashbariHHamdiSDarrajH, et al. Knowledge, attitude and practices towards surgical wound care and healing among the public in the Jazan Region, Saudi Arabia. Medicine (Baltimore)2023; 102: e36776.
26.
McLeanKASgròABrownLR, et al. Evaluation of remote digital postoperative wound monitoring in routine surgical practice. NPJ Digit Med2023; 6: 85.
27.
CoubeMNikoloskiZMrejenM, et al. Inequalities in unmet need for health care services and medications in Brazil: a decomposition analysis. Lancet Reg Health Am2023; 19: 100426.
28.
MikhailARLegareTTanamalP, et al. Femoral vein translocation for complex hemodialysis access. J Vasc Surg2024; 80: 847–854.e1.
29.
OrionKCKimTIRizzoAN, et al. Long-term outcomes of transposed femoral vein arteriovenous fistula for abandoned upper extremity dialysis access. J Vasc Surg2021; 74: 225–229.
30.
FarberAChengTWNimmichA, et al. Femoral vein transposition is a durable hemodialysis access for patients who have exhausted upper extremity options. J Vasc Surg2020; 71: 929–936.
31.
AntoniouGALazaridesMKGeorgiadisGS, et al. Lower-extremity arteriovenous access for haemodialysis: a systematic review. Eur J Vasc Endovasc Surg2009; 38: 365–372.
32.
GageSMKatzmanHERossJR, et al. Multi-center experience of 164 consecutive Hemodialysis Reliable Outflow [HeRO] graft implants for hemodialysis treatment. Eur J Vasc Endovasc Surg2012; 44: 93–99.
33.
HunterJPKnightSRInstonN, et al. The United Kingdom and Ireland experience of the Haemodialysis Reliable Outflow graft for vascular access. J Vasc Access2019; 20: 12–18.
34.
MatoussevitchVDorweilerBKalmykovE.HeRO graft-the results of the cologne single center study. Vascular2025; 33(4): 879–885.
35.
GrimaMJVriensBHoltPJ, et al. An arterioarterial prosthetic graft as an alternative option for haemodialysis access: a systematic review. J Vasc Access2018; 19: 45–51.
36.
MurakamiMMoriKHamanoueS, et al. Multicentre study on the efficacy of brachial artery transposition among haemodialysis patients. Eur J Vasc Endovasc Surg2021; 61: 998–1006.
37.
NakamuraTSuemitsuKNakamuraJ.Superficialization of brachial artery as effective alternative vascular access. J Vasc Surg2014; 59: 1385–1392.
38.
AliHElbadawyASalehM.Midterm outcomes of brachial arterio-arterial prosthetic loop as permanent hemodialysis access. J Vasc Surg2020; 72: 181–187.
39.
HarduinLOBarrosoTAGuerraJB, et al. Safety and efficacy of a new covered stent in hemodialysis vascular access outflow stenosis: a Brazilian multicenter retrospective study. J Vasc Access2025; 26(2): 510–518.
40.
HuxleyVH.Sex and the cardiovascular system: the intriguing tale of how women and men regulate cardiovascular function differently. Adv Physiol Educ2007; 31: 17–22.
